A study to assess Immune-Related Adverse Effects of Immunotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma
Latest Information Update: 04 Mar 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer